Researchers at Johns Hopkins University have developed an integrated genomic approach that potentially could help physicians predict which patients with non-small cell lung cancer will respond to therapy with immune checkpoint inhibitors.
As NCI paylines drop to 4%, cancer centers are tapping into their institutional funds to provide “bridge funding,” typically in $50,000 to $100,000 increments, to enable investigators to keep their labs open until better times return—next year God willing.
